NeuroBo Pharmaceuticals announced that it has appointed Joseph Hooker as Interim CEO and President. Hooker’s appointment follows Gil Price, M.D.’s decision to retire from his position as President and CEO of NeuroBo. NeuroBo’s Board of Directors plans to initiate a candidate search with the assistance of a leading executive search firm to identify Dr. Price’s permanent successor. Hooker has served as an independent consultant and advised on an ad hoc basis for leading management consultancies and various pharmaceutical companies with respect to clinical trials, CROs and program management. Previously, Hooker was Sr. Director of Clinical Operations/Program Leader Rare Disease, Oncology for X4 Pharmaceuticals, Inc., where he led a cross-functional global program team, pre-clinical through development and commercialization, including strategic planning, oversight, execution of clinical operations and the management of staff.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NRBO:
